Highly Collaborative Clinical Network
The MMRC is the first research model that brings together 16 leading academic centers with industry partners to conduct highly collaborative phase 1 and phase 2 clinical trials of novel compounds and combination treatments for multiple myeloma.
All centers are driven by highly defined metrics that mandate accountability and strongly promote team science. The MMRC has launched more than 40 trials of today’s most promising novel compounds and combinations. More than 1,100 patients have enrolled in these trials to date. Notably, recent trials were opened 60% faster, or approximately 100 days sooner than the industry benchmark in oncology, and enrolled 14% faster, or two months sooner, than our commitment.
In July 2012, the MMRC model received important validation. Kyprolis™ (carfilzomib) for Injection received FDA approval for the treatment of patients with advanced multiple myeloma as the fifth new treatment approved for the disease in less than 10 years. Since 2006, the MMRC had bolstered Kyprolis’ clinical development by providing critical clinical trial support and resources, including driving accrual to the pivotal Phase 2b trial that supported the accelerated approval of the treatment.
Five additional drugs studied in early-stage MMRC trials have also advanced to Phase 3 clinical trials. One of these, pomalidomide, is under consideration for accelerated approval based on data from a pivotal Phase 2 whose enrollment was largely driven by MMRC participation in the trial.